New hope for ovarian cancer: Real-World niraparib study shows promise
NCT ID NCT06086665
First seen Feb 04, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study looked at how well the drug niraparib works and its safety in 850 Korean women with ovarian cancer. It included patients who received niraparib as maintenance therapy after initial treatment or as a later treatment. The researchers measured how long patients lived without the cancer getting worse and tracked side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, 138-736, South Korea
Conditions
Explore the condition pages connected to this study.